Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DNLI
DNLI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNLI News
Biotech Landscape Update: Regulatory Approvals and Mergers
3d ago
NASDAQ.COM
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah
4d ago
Newsfilter
Denali Receives FDA Accelerated Approval for AVLAYAH
4d ago
NASDAQ.COM
FDA Approves First Treatment for Hunter Syndrome in Nearly 20 Years
5d ago
Newsfilter
Denali Therapeutics Receives FDA Approval for Avlayah™ (Tividenofusp Alfa-Eknm) to Treat Hunter Syndrome (MPS II)
5d ago
moomoo
Denali Therapeutics Receives FDA Approval for New Drug
5d ago
seekingalpha
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
6d ago
PRnewswire
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
6d ago
Newsfilter
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
Mar 09 2026
Benzinga
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
Mar 06 2026
CNBC
FDA Drug Approval Uncertainty Intensifies
Mar 06 2026
Newsfilter
Denali Therapeutics Reports Q4 Results and Stock Offering
Feb 26 2026
seekingalpha
Shifting Trends in Biotechnology Mergers and Acquisitions
Feb 19 2026
Globenewswire
REGENXBIO Faces FDA Challenges for Gene Therapy Approval
Feb 10 2026
Newsfilter
REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
Feb 10 2026
Benzinga
Denali Therapeutics Advances in Hunter Syndrome Treatment
Feb 05 2026
Newsfilter
Show More News
